A Single-Blinded Randomized Clinical Trial Comparing Polymyxin B-Trimethoprim and Moxifloxacin for Treatment of Acute Conjunctivitis in Children - 25/03/13
, Yogangi Malhotra, MD 1, 5, , Barbra Murante, NP 1, Susan Laverty, RN 1, Steve Cook, MD 1, David Topa, MD 1, 2, Dwight Hardy, PhD 3, Hongyue Wang, PhD 4, Francis Gigliotti, MD 1, 3, ⁎ 
Reprint requests: Francis Gigliotti, MD, Department of Pediatrics, Golisano Children’s Hospital at Strong, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 690, Rochester, NY 14642.Abstract |
Objective |
To perform a randomized controlled trial comparing moxifloxacin hydrochloride with polymyxin B-trimethoprim for the treatment of acute conjunctivitis.
Study design |
Patients ages 1-18 years old with acute conjunctivitis had cultures performed and were randomized to receive either moxifloxacin hydrochloride or polymyxin B-trimethoprim ophthalmic solution for 7 days. Response to treatment was determined by phone query on day 4-6 and by examination with post-treatment conjunctival culture on day 7-10.
Results |
One hundred and twenty-four patients were enrolled. Eighty patients (65%) had recognized pathogens (55 Haemophilus influenzae, 22 Streptococcus pneumoniae, 4 Moraxella catarrhalis) isolated from their conjunctiva. One hundred fourteen (56/62 moxifloxacin and 58/62 polymyxin B-trimethoprim) completed the 4-6 day evaluation, with 43/56 (77%) of the moxifloxacin group and 42/58 (72%) of the polymyxin B-trimethoprim group clinically cured according to parents (noninferiority test P = .04). Eighty-nine (39/56 moxifloxacin and 50/58 polymyxin B-trimethoprim) patients completed the 7-10 day evaluation. Clinical cure was observed in 37/39 (95%) of the moxifloxacin and 49/51 (96%) of the polymyxin B-trimethoprim treated groups (noninferiority test P ≤ .01). Clinical cure rates for culture positive and negative conjunctivitis were not different. There was no statistically significant difference in bacteriologic cure rates between the 2 groups.
Conclusions |
Polymyxin B-trimethoprim continues to be an effective treatment for acute conjunctivitis with a clinical response rate that does not differ from moxifloxacin. Use of polymyxin B-trimethoprim for the treatment of conjunctivitis would result in significant cost savings compared with fluoroquinolones.
Le texte complet de cet article est disponible en PDF.Keyword : MIC
Plan
| Y.M. is supported in part by a resident research grant from the American Academy of Pediatrics. The authors declare no conflicts of interest. |
Vol 162 - N° 4
P. 857-861 - avril 2013 Retour au numéro
Article précédent
- Pediatric Anti-N-methyl-D-Aspartate Receptor Encephalitis—Clinical Analysis and Novel Findings in a Series of 20 Patients
- Thaís Armangue, Maarten J. Titulaer, Ignacio Málaga, Luis Bataller, Iñigo Gabilondo, Francesc Graus, Josep Dalmau, Spanish Anti-N-methyl-D-Aspartate Receptor (NMDAR) Encephalitis Work Group ∗
- Alarming Signs in the Manchester Triage System: A Tool to Identify Febrile Children at Risk of Hospitalization
- Yvette van Ierland, Nienke Seiger, Mirjam van Veen, Henriëtte A. Moll, Rianne Oostenbrink
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?